Table 2.

Percentage concordance of Euro-GASP centralised testing and laboratories’ own antimicrobial susceptibility testing results

Year	Ceftriaxone	Azithromycin	Cefixime	Ciprofloxacin	Spectinomycin	Gentamicin	β-lactamase
2006	87.6–100	95.3–100	–	49.5–99.1	–	–	96.3–100
2007	95.3–100	75.6–100	–	90.3–100	–	–	100
2008	93.8–100	41.7–100	–	94.2–100	100	–	98–100
2009	95.8–100	87–100	100	92.9–100	100	100	97.5–100
2010	93.8–100	89.1–100	97.1–100	92.6–100	100	100	98.2–100
2012	95.8–100	75a – 100	95.8–100	80b - 100	100	98.1–100	97.9–98.1
2013	95.4–100	89a - 100	95.5–100	80b - 100	100	97.3–100	99.1–100

The table contains data from; Austria (2012–2013, all antimicrobials); Belgium (2006–2009, no gentamicin or cefixime data); Cyprus (2012–2013, no spectinomycin, gentamicin or β-lactamase data); Denmark (2006–2009, ceftriaxone, ciprofloxacin and β-lactamase data only); France (2008–2010, no azithromycin or gentamicin data); Greece (2007–2010, no gentamicin data); Iceland (2012–2013, no spectinomycin, gentamicin or β-lactamase data); Ireland (2012, ceftriaxone, azithromycin and cefixime data only); Italy (2007, azithromycin and ciprofloxacin only, 2010–2011 all antimicrobials); Malta (2012–2013, no gentamicin or β-lactamase data); Norway (2012–2013, no β-lactamase data); Portugal (2009–2010, no azithromycin data); Slovenia (2011–2013, all antimicrobials); Spain (2006–2009, no cefixime or gentamicin data); Sweden (2006–2009, no cefixime or gentamicin data); The Netherlands (2006–2010, ceftriaxone, ciprofloxacin and β-lactamase data only) and the UK (2006–2010, no gentamicin data). Data from Slovenia was only available for 2011 so data is not shown, however all concordances for 2011 were within specified limits

^aAll discrepant isolates on the resistance breakpoint

^bOnly a very low number of isolates available for comparison from two labs, so 1–2 mismatches resulted in only 80% concordance, however overall concordance of the resistance category comparisons was ≥97%